DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Briakinumab
Briakinumab
Recent Advances in Inflammatory Bowel Disease: Mucosal Immune
Biologic Armamentarium in Psoriasis
Australian Public Assessment Report for Ixekizumab
USTEKINUMAB and BRIAKINUMAB (ABT-874) TARGET P40, the SUBUNIT SHARED by IL-23 and IL-12
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
The Two Tontti Tudiul Lui Hi Ha Unit
Association of Ustekinumab and Briakinumab with Major Adverse
Monoclonal Antibodies As Neurological Therapeutics
Novel Psoriasis Therapies and Patient Outcomes, Part 2: Biologic Treatments
Charge-Mediated Influence of the Antibody Variable Domain on Fcrn-Dependent Pharmacokinetics
FDA Briefing Document Dermatologic and Ophthalmic Drugs Advisory
(INN) for Biological and Biotechnological Substances
Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of Ro5459072 in Patients with Primary Sjögren’S Syndrome
Briakinumab for Treatment of Crohn's Disease: Results of a Randomized
INN Working Document 05.179 Update 2011
Standards, Perspektiven Und Grenzen Der Konservativen Therapie
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
211 the Impact of Biological Interventions on Health-Related Quality of Life in Adults with Crohn's Disease
Top View
(INN) for Biological and Biotechnological Substances
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
Biologic Therapy for Psoriatic Arthritis Or Moderate to Severe Plaque Psoriasis: Systematic Review with Pairwise and Network Meta-Analysis
Evidence-Based Practice Center Systematic Review Protocol
Differential Response of Chronic Plaque Psoriasis to Briakinumab Vs
Defining the Role of Interleukin 17 in Rheumatoid Arthritis
Effect of Disease Modifying Anti-Rheumatic Drugs On
1 Brodalumab in Psoriatic Arthritis: Results from the Randomised Phase
ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
204824Orig2s000
Role of IL-23 Neutralization in Psoriasis – Insights from a 2 Mechanistic PK/PD Model and Meta-Analysis of Clinical Data
Drug Class Review Targeted Immune Modulators
Kinase Inhibition in Autoimmunity and Inflammation
Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases
Covid-19 and Patients Undergoing Pharmacological Treatments for Immune-Mediated Inflammatory Diseases: Protocol for a Rapid Living Systematic Review
CV Blauvelt 1219
125521Orig1s000
Biologics for Psoriasis and Psoriatic Arthritis (Adalimumab, Etanercept, Golimumab, Infliximab, Ustekinumab)
New Systemic Therapies for Psoriasis
FDA Presentations for the July 19, 2016 Meeting of the Dermatologic
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Covid-19 and Patients Undergoing Pharmacological Treatments for Immune-Mediated Inflammatory Diseases: Protocol for a Rapid Living Systematic Review
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
Anti-P40 Antibodies Ustekinumab and Briakinumab
(INN) for Biological and Biotechnological Substances
Supporting Information the Therapeutic Antibody Profiler (TAP): Five Computational De- Velopability Guidelines
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-To-Severe Plaque Psoriasis
Successful Intra-Class Switching Among IL-17 Antagonists: a Multicentre, Multinational, Retrospective Study
Assessment of the Evolution of Cancer Treatment Therapies
A CME/CE-Certified Supplement to Dermatology News
Cytokine Targeting in Rheumatoid Arthritis T ⁎ Viet L
Compounds and Methods for Treating Inflammatory
(CIMZIA) in Psoriatic Arthritis Monograph
COVID-19 and Patients with Immune-Mediated Inflammatory
(12) 按照专利合作条约所公布的国际申请w O 2016/050208
761032Orig1s000
Old and New Treatment Targets in Axial Spondyloarthritis
Targeted Immunomodulators for the Treatment of Moderate-To-Severe Plaque Psoriasis: Effectiveness and Value
Short-Term Risk of Major Adverse Cardiovascular Events Or Congestive